Studie

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) P

Erkrankungsgruppe:

Leukämien und MDS

Organsystem:

Blut

Stadium:

Rückfall, Therapierefraktär

Standort:

Essen

EudraCT:

2018-002301-61

Prüfplan-Code:

2215-CL-0603

Phase:

I/II

Prüfsubstanz:

Gliteritinib

Sponsor:

Astellas